JP2012019790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012019790A5 JP2012019790A5 JP2011178553A JP2011178553A JP2012019790A5 JP 2012019790 A5 JP2012019790 A5 JP 2012019790A5 JP 2011178553 A JP2011178553 A JP 2011178553A JP 2011178553 A JP2011178553 A JP 2011178553A JP 2012019790 A5 JP2012019790 A5 JP 2012019790A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- flt4
- tissue
- bound
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 210000002889 endothelial cell Anatomy 0.000 claims description 8
- 230000001613 neoplastic effect Effects 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 101150009958 FLT4 gene Proteins 0.000 claims description 7
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 230000003511 endothelial effect Effects 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 3
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 claims 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101600105505 Mus musculus Vascular endothelial growth factor C (isoform 1) Proteins 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/169,079 | 1998-10-09 | ||
| US09/169,079 US6824777B1 (en) | 1992-10-09 | 1998-10-09 | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000575533A Division JP4841724B2 (ja) | 1998-10-09 | 1999-10-08 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012019790A JP2012019790A (ja) | 2012-02-02 |
| JP2012019790A5 true JP2012019790A5 (enExample) | 2012-08-23 |
| JP5642637B2 JP5642637B2 (ja) | 2014-12-17 |
Family
ID=22614189
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000575533A Expired - Fee Related JP4841724B2 (ja) | 1998-10-09 | 1999-10-08 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） |
| JP2011000273A Expired - Lifetime JP5784310B2 (ja) | 1998-10-09 | 2011-01-04 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） |
| JP2011178553A Expired - Fee Related JP5642637B2 (ja) | 1998-10-09 | 2011-08-17 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） |
| JP2013097900A Pending JP2013209382A (ja) | 1998-10-09 | 2013-05-07 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） |
| JP2015077656A Pending JP2015157829A (ja) | 1998-10-09 | 2015-04-06 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000575533A Expired - Fee Related JP4841724B2 (ja) | 1998-10-09 | 1999-10-08 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） |
| JP2011000273A Expired - Lifetime JP5784310B2 (ja) | 1998-10-09 | 2011-01-04 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013097900A Pending JP2013209382A (ja) | 1998-10-09 | 2013-05-07 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） |
| JP2015077656A Pending JP2015157829A (ja) | 1998-10-09 | 2015-04-06 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US8444957B2 (enExample) |
| EP (1) | EP1119371B1 (enExample) |
| JP (5) | JP4841724B2 (enExample) |
| CN (1) | CN100340291C (enExample) |
| AT (1) | ATE489108T1 (enExample) |
| AU (2) | AU774266B2 (enExample) |
| CA (1) | CA2345276C (enExample) |
| DE (1) | DE69942981D1 (enExample) |
| DK (1) | DK1119371T3 (enExample) |
| ES (1) | ES2357406T3 (enExample) |
| NO (1) | NO20011759L (enExample) |
| NZ (2) | NZ511408A (enExample) |
| WO (1) | WO2000021560A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060950A2 (en) | 1994-11-14 | 2002-08-08 | Ludwig Institute For Cancer Research | Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy |
| US6818220B1 (en) | 1994-11-14 | 2004-11-16 | Licentia Ltd. | Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof |
| US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| ATE242809T1 (de) | 1995-09-08 | 2003-06-15 | Genentech Inc | Vegf-verwandtes protein |
| US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
| CA2345276C (en) * | 1998-10-09 | 2011-03-29 | Ludwig Institute For Cancer Research | Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy |
| US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
| EP1553414A1 (en) * | 1999-04-13 | 2005-07-13 | Medarex, Inc. | Methods for the diagnosis and treatment of metastatic prostate tumors |
| US6965010B2 (en) | 2000-02-25 | 2005-11-15 | Licentia, Ltd. | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
| CN1211126C (zh) | 2000-08-04 | 2005-07-20 | 人体基因组科学有限公司 | 血管内皮生长因子2 |
| US7611711B2 (en) | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
| WO2002083704A1 (en) | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| WO2005078097A2 (en) | 2004-02-10 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA) |
| US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| WO2003002144A1 (en) * | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
| US20030113324A1 (en) * | 2001-10-01 | 2003-06-19 | Kari Alitalo | Neuropilin/VEGF-C/VEGFR-3 materials and methods |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US8003613B2 (en) | 2003-11-17 | 2011-08-23 | University Of Florida Research Foundation, Inc. | Methods and compositions for inducing apoptosis |
| US20060024302A1 (en) | 2004-03-05 | 2006-02-02 | Ludwig Institute For Cancer Research | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
| US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| DE602006020881D1 (de) | 2005-08-15 | 2011-05-05 | Vegenics Pty Ltd | Enen eigenschaften |
| US7629125B2 (en) | 2006-11-16 | 2009-12-08 | General Electric Company | Sequential analysis of biological samples |
| US8305579B2 (en) | 2006-11-16 | 2012-11-06 | Thomas Pirrie Treynor | Sequential analysis of biological samples |
| US9201063B2 (en) | 2006-11-16 | 2015-12-01 | General Electric Company | Sequential analysis of biological samples |
| US9677125B2 (en) | 2009-10-21 | 2017-06-13 | General Electric Company | Detection of plurality of targets in biological samples |
| WO2011106697A1 (en) | 2010-02-25 | 2011-09-01 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| WO2014064203A1 (en) | 2012-10-26 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
| SMT202000088T1 (it) | 2013-02-18 | 2020-03-13 | Vegenics Pty Ltd | Molecole leganti ligandi e relativi usi |
| US10274503B2 (en) | 2013-05-08 | 2019-04-30 | Vegenics Pty Limited | Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis |
| KR102131370B1 (ko) | 2013-10-18 | 2020-07-08 | 삼성전자주식회사 | Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도 |
| CN114262683B (zh) * | 2022-03-01 | 2022-06-17 | 中国科学院动物研究所 | 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4652639A (en) * | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
| US4543439A (en) * | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| DE3587657D1 (de) * | 1984-01-30 | 1993-12-23 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
| JP2736255B2 (ja) * | 1987-03-11 | 1998-04-02 | フアルマシア・エ・アツプジヨン・エツセ・ピー・アー | イムノグロブリン結合体 |
| EP0325224B1 (en) | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Methods of producing secreted receptor analogs |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2011450C (en) * | 1989-03-07 | 2002-06-04 | Tadatsugu Taniguchi | Recombinant b-chain of the il-2 receptor |
| EP0474744B1 (en) | 1989-05-22 | 1994-08-03 | Zymogenetics, Inc. | Pdgf -alpha- receptor |
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| DK0584082T3 (da) | 1991-01-31 | 2000-10-16 | Univ California | Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider |
| US5256766A (en) * | 1991-02-19 | 1993-10-26 | The Regents Of The University Of California | Recombinant thrombin receptor and related pharmaceuticals |
| WO1992014748A1 (en) | 1991-02-22 | 1992-09-03 | American Cyanamid Company | Identification of a novel human receptor tyrosine kinase gene |
| US5231001A (en) * | 1991-03-14 | 1993-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor |
| US5270458A (en) * | 1991-04-02 | 1993-12-14 | The Trustees Of Princeton University | Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2 |
| US5185438A (en) * | 1991-04-02 | 1993-02-09 | The Trustees Of Princeton University | Nucleic acids encoding hencatoporetic stem cell receptor flk-2 |
| US5367057A (en) * | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
| CA2078539C (en) * | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| AU3353293A (en) | 1992-01-09 | 1993-08-03 | Helsinki University Holding, Ltd. | Tie, a novel endothelial cell receptor tyrosine kinase |
| CA2128722A1 (en) | 1992-01-22 | 1993-08-05 | William I. Wood | Novel protein tyrosine kinases |
| US5635177A (en) * | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| US6331302B1 (en) * | 1992-01-22 | 2001-12-18 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| US5660827A (en) * | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
| US5776755A (en) * | 1992-10-09 | 1998-07-07 | Helsinki University Licensing, Ltd. | FLT4, a receptor tyrosine kinase |
| US6824777B1 (en) * | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| EP0666868B2 (en) | 1992-10-28 | 2006-06-14 | Genentech, Inc. | Use of anti-VEGF antibodies for the treatment of cancer |
| US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| DE4337197C1 (de) * | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| ATE309360T1 (de) | 1994-03-08 | 2005-11-15 | Human Genome Sciences Inc | Vaskularer endothelialer wachstumsfaktor 2 |
| US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
| GB9410534D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
| JP3723210B2 (ja) * | 1994-06-09 | 2005-12-07 | ヘルシンキ ユニバシティ ライセンシング リミテッド オサケ ユキチュア | 受容体チロシンキナーゼであるｆｌｔ４ならびに診断および治療におけるその使用 |
| US5763733A (en) * | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
| US6645933B1 (en) | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
| WO1998033917A1 (en) | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
| ATE242809T1 (de) | 1995-09-08 | 2003-06-15 | Genentech Inc | Vegf-verwandtes protein |
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| AU3968597A (en) * | 1996-08-02 | 1998-02-25 | Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
| CA2263890C (en) | 1996-08-23 | 2013-05-14 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor d (vegf-d) |
| CN1345247A (zh) | 1997-12-24 | 2002-04-17 | 路德维格癌症研究所 | 表达血管内皮生长因子d的表达载体和细胞系以及治疗黑素瘤的方法 |
| CA2345276C (en) * | 1998-10-09 | 2011-03-29 | Ludwig Institute For Cancer Research | Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy |
| KR101681886B1 (ko) | 2015-04-06 | 2016-12-12 | 서울대학교산학협력단 | 지르코니아 결합능을 가지는 펩타이드 |
-
1999
- 1999-10-08 CA CA2345276A patent/CA2345276C/en not_active Expired - Fee Related
- 1999-10-08 AU AU13121/00A patent/AU774266B2/en not_active Ceased
- 1999-10-08 NZ NZ511408A patent/NZ511408A/en unknown
- 1999-10-08 EP EP99956525A patent/EP1119371B1/en not_active Expired - Lifetime
- 1999-10-08 NZ NZ529063A patent/NZ529063A/en unknown
- 1999-10-08 AT AT99956525T patent/ATE489108T1/de active
- 1999-10-08 ES ES99956525T patent/ES2357406T3/es not_active Expired - Lifetime
- 1999-10-08 DK DK99956525.2T patent/DK1119371T3/da active
- 1999-10-08 WO PCT/US1999/023525 patent/WO2000021560A1/en not_active Ceased
- 1999-10-08 JP JP2000575533A patent/JP4841724B2/ja not_active Expired - Fee Related
- 1999-10-08 DE DE69942981T patent/DE69942981D1/de not_active Expired - Lifetime
- 1999-10-08 CN CNB998142859A patent/CN100340291C/zh not_active Expired - Fee Related
-
2001
- 2001-04-06 NO NO20011759A patent/NO20011759L/no unknown
-
2004
- 2004-09-03 AU AU2004208675A patent/AU2004208675B2/en not_active Ceased
-
2010
- 2010-02-17 US US12/707,423 patent/US8444957B2/en not_active Expired - Fee Related
-
2011
- 2011-01-04 JP JP2011000273A patent/JP5784310B2/ja not_active Expired - Lifetime
- 2011-08-17 JP JP2011178553A patent/JP5642637B2/ja not_active Expired - Fee Related
-
2013
- 2013-04-18 US US13/865,711 patent/US20140072511A1/en not_active Abandoned
- 2013-05-07 JP JP2013097900A patent/JP2013209382A/ja active Pending
-
2014
- 2014-10-01 US US14/504,028 patent/US20150158928A1/en not_active Abandoned
-
2015
- 2015-04-06 JP JP2015077656A patent/JP2015157829A/ja active Pending
- 2015-12-29 US US14/982,422 patent/US20160184405A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012019790A5 (enExample) | ||
| JP2011121957A5 (enExample) | ||
| Paulitti et al. | The ablation of the matricellular protein EMILIN2 causes defective vascularization due to impaired EGFR-dependent IL-8 production affecting tumor growth | |
| Silini et al. | Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor’s proangiogenic microenvironment | |
| Wang et al. | Microarray based screening of peptide nano probes for HER2 positive tumor | |
| JP2015533788A5 (enExample) | ||
| AU2023202602A1 (en) | Combination therapy using inhibitors of human Growth and Differentiation factor 15 (GDF-15) and immune checkpoint blockers | |
| HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
| JP2013539468A5 (enExample) | ||
| JP2009539082A5 (enExample) | ||
| Srivastava et al. | Pharmacodynamic response of the MET/HGF receptor to small-molecule tyrosine kinase inhibitors examined with validated, fit-for-clinic immunoassays | |
| EP3194974A1 (en) | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer | |
| JP2017520763A5 (enExample) | ||
| JP2011511762A5 (enExample) | ||
| JP2018516244A5 (enExample) | ||
| Zhou et al. | The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models | |
| Zhao et al. | A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer | |
| JPWO2021075545A5 (enExample) | ||
| WO2019065747A1 (ja) | 抗ｃｋａｐ４モノクローナル抗体 | |
| JP2012531612A5 (enExample) | ||
| WO2014205342A4 (en) | Methods for treatment of ovarian cancer | |
| Lynce et al. | Pertuzumab for the treatment of breast cancer | |
| Angelescu et al. | VEGF-A and VEGF-B mRNA expression in gastro-oesophageal cancers | |
| Di Stadio et al. | AMP18 interacts with the anion exchanger SLC26A3 and enhances its expression in gastric cancer cells | |
| Wang et al. | An apparent clinical pharmacokinetic drug–drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism |